MMAE （monomethyl auristatin E） is an antimitotic agent that binds to tubulin and inhibits the assembly of microtubules.
Mc-VC-PAB-MMAE is a thiol reactive derivative of MMAE that contains a cathepsin cleavable valine-citrulline p-aminobenzylcarbamate linkage.
Mc-VC-PAB-MMAE is used to prepare antibody-drug conjugates, such as brentuximab vedotin （Seattle Genetics）.
This BSA-MMAE conjugate is designed with similar linker chemistry as ADCs synthesized at CellMosaic® for our customers' usage in immunization or immunoassay.
Thiol functional groups are introduced to the BSA followed by reaction of the maleimide group of Mc-VC-PAB-MMAE to form the conjugate.The final conjugate is lyophilized from phosphate buffered saline containing sugar-based stabilizer for easy shipping and storage.
The product is sold as 1 vial of 1 mg （Cat# CM52113-1MG） or 5 vials of 1 mg （Cat# CM52113-5MG）.
